Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral- naïve patients: A 48-week pilot study

HIV Clinical Trials

Volumn 9, Issue 3, 2008, Pages 152-163

  Elion, Richard ^a,h   DeJesus, Edwin ^b   Sension, Michael ^c   Berger, Daniel ^d   Towner, William ^e   Richmond, Gary ^f   Clair, Marty St ^g   Yau, Linda ^g   Ha, Belinda ^g  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b ORLANDO IMMUNOLOGY CENTER   (United States)

^c Comprehensive Care Center ^*  (United States)

^d Northstar Medical Center   (United States)

^e KAISER PERMANENTE   (United States)

^f Broward General Medical Center   (United States)

^g GLAXOSMITHKLINE   (United States)

^h NONE   (United States)

Author keywords

Abacavir lamivudine; Atazanavir; Insulin resistance; Lipids; Ritonavir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; AMPRENAVIR PHOSPHATE; ATAZANAVIR; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RITONAVIR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE JAUNDICE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ADULT; AGED; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; OLIGOPEPTIDES; PILOT PROJECTS; PYRIDINES; RITONAVIR;

EID: 45949088368     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0903-152     Document Type: Article

References (29)

1. Department of Heath and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2007. http://aidsinfo.nih.gov/
2. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV-infected adults in Europe. December 2007. http://www.eacs.eu/guide/index.htm
3. Dube MR Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627.
4. Agarwala S, Russo R, Mummaneni V, et al. Steady-state pharmacokinetic (PK) interaction of atazanavir (ATV) with ritonavir (RTV) in healthy subjects. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002; San Diego, CA. Abstract H-1716.
5. Badaro R, DeJesus E, Lazzarin A, et al. Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in combination with tenofovir (TFV) and one NRTI in patients who have experienced virologic failure to multiple HAART regimens: 16-week results from BMS AI424-045. In: 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract 118.
6. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685-694.
7. Johnson M, Grinsztein B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twicedaily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20:711-718.
8. Malan N, Krantz E, David N, et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 lnfected subjects, both with and without ritonavir: 48-week results from AI424-089. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colorado. Abstract 107LB.
9. Smith K, Weinberg W, Dejesus E, et al. Once-daily ritonavir (100 mg) boosting of fosamprenavir (FPV/r) or atazanavir (ATZ/r) with tenofovir(TDF)/emtricitabine(FTC) in antiretroviral-naive HIV-infected patients: 48-week safety/efficacy results from COL103952 (ALERT). In: Abstracts of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WEPEB023.
10. Elion R, Cohen C, Ward D, et al. Evaluation of the efficacy, safety, pharmacokinetics (PK), adherence, and treatment satisfaction with boosted atazanavir (ATV/r) and fixed-dose emtricitabine/tenofovir DF (FTC/TDF) given once-daily (QD) in HIV infected, antiretroviral (ARV) naïve subjects: Final results of BATON. In: Abstracts of the 11th European AIDS Conference; October 24-27, 2007; Madrid, Spain. Abstract P7.3/20.
11. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38:263-270.
12. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004;18:1029-1036.
13. Shlay JC, Visnegarwala F, Bartsch G, et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr. 2005;38:I47-155.
14. Podzamczer D, Ferrer E, Sanchez R et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr. 2007;44:139-147.
15. Hirsch MS, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37:113-128.
16. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study question for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-254.
17. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402-2410.
18. Matthews DR, Hosker JR Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
19. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476-482.
20. Jones CY, Wilson IB, Greenberg AS, et al. Insulin resistance in HIV-infected men and women in the Nutrition for Healthy Living Cohort. J Acquir Immune Defic Syndr. 2005;40:202-211.
21. Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naïve HIV-infected subjects. Clin Infect Dis. 2006;42:273-280.
22. McGrath D, Frederick D, Wirtz V, et al. Body composition changes in ART-naïve subjects treated with atazanavir or atazanavir/ritonavir-based once-daily HAART: 48-week computer tomography and DEXA data. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, California. Abstract 804.
23. Wohl D, Lancaster T, Dejesus E, et al. Determination of body composition changes by total body DEXA after 48 weeks of treatment with once-daily fosamprenavir (FPV) boosted with two different doses of ritonavir(r) plus abacavir (ABC)/lamivudine(3TC): COL100758. In: Abstracts of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention Sydney; July 22-25, 2007; Australia. Abstract TUPEB080.
24. Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep. 2004;6:381-387.
25. Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol. 2002;90:22i-29i.
26. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics. 2004;5:203-211.
27. Reeves I, Churchill D, Fisher M. Clinical utility of HLA-B*5701 testing in a UK clinic cohort. Poster presentation at 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colorado. Poster abstract 667a.
28. Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reaction in the western Australian HIV cohort study. Clin Infect Dis. 2006;43:99-102.
29. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008; 358:568-579.